Outcome of Critically Ill COVID-19 Patients According to the Setting of Corticosteroid Initiation-A Retrospective Observational Cohort Study.
COVID-19
corticosteroid
dexamethasone
intensive care unit
mortality
survival
Journal
Journal of personalized medicine
ISSN: 2075-4426
Titre abrégé: J Pers Med
Pays: Switzerland
ID NLM: 101602269
Informations de publication
Date de publication:
13 Dec 2021
13 Dec 2021
Historique:
received:
24
10
2021
revised:
28
11
2021
accepted:
07
12
2021
entrez:
24
12
2021
pubmed:
25
12
2021
medline:
25
12
2021
Statut:
epublish
Résumé
(1) Background: Corticosteroids lower 28-day all-cause mortality in critically ill COVID-19 patients. However, the outcome of COVID-19 patients referred to the intensive care unit (ICU) for respiratory deterioration despite corticosteroids initiated during hospitalization before ICU admission has been poorly investigated. Our objective was to determine survival according to corticosteroid initiation setting. (2) Methods: We conducted a cohort study including all successive critically ill COVID-19 patients treated with corticosteroids and managed in our ICU. We compared survival, whether corticosteroids were initiated before (Cb-group) or after ICU admission (Ca-group), using a propensity score matching. (3) Results: Overall, 228 patients (67 years (56-74); 168M/60F; invasive mechanical ventilation on admission, 17%) were included with 63 patients in the Cb-group and 165 patients in the Ca-group. Survival to hospital discharge was 43% versus 69%, respectively (
Identifiants
pubmed: 34945831
pii: jpm11121359
doi: 10.3390/jpm11121359
pmc: PMC8706060
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Lancet Respir Med. 2021 Mar;9(3):295-304
pubmed: 33493450
JAMA Netw Open. 2021 Apr 1;4(4):e216468
pubmed: 33885775
Intensive Care Med. 2021 Jan;47(1):60-73
pubmed: 33211135
Medicine (Baltimore). 2021 Aug 13;100(32):e26900
pubmed: 34397917
Lancet Respir Med. 2020 Mar;8(3):267-276
pubmed: 32043986
JAMA. 2012 Jun 20;307(23):2526-33
pubmed: 22797452
Lancet Respir Med. 2020 Nov;8(11):1121-1131
pubmed: 32798468
Intensive Care Med. 1996 Jul;22(7):707-10
pubmed: 8844239
Am J Respir Crit Care Med. 2020 Oct 1;202(7):1039-1042
pubmed: 32758000
JAMA. 2021 Aug 10;326(6):499-518
pubmed: 34228774
Pharm Stat. 2011 Mar-Apr;10(2):150-61
pubmed: 20925139
N Engl J Med. 2021 Apr 22;384(16):1491-1502
pubmed: 33631065
N Engl J Med. 2021 Feb 25;384(8):693-704
pubmed: 32678530
BMJ Open Respir Res. 2019 May 24;6(1):e000420
pubmed: 31258917
Respirol Case Rep. 2020 Jun 04;8(6):e00596
pubmed: 32514354
Lancet Respir Med. 2021 Aug;9(8):851-862
pubmed: 33887246
PLoS One. 2021 Jan 28;16(1):e0243964
pubmed: 33507958
Intensive Care Med. 2021 Aug;47(8):867-886
pubmed: 34251506
Int J Gen Med. 2021 Jun 08;14:2359-2366
pubmed: 34135619
Science. 2021 Jul 16;373(6552):
pubmed: 34103349
JAMA. 2020 Oct 6;324(13):1317-1329
pubmed: 32876697
JAMA. 2020 Oct 6;324(13):1330-1341
pubmed: 32876694
Eur Respir J. 2020 Sep 24;56(3):
pubmed: 32747391
Int J Oncol. 2021 Feb;58(2):145-157
pubmed: 33491759
Ann Intensive Care. 2019 Jun 13;9(1):69
pubmed: 31197492
PLoS One. 2021 May 25;16(5):e0252057
pubmed: 34033648
Clin Infect Dis. 2021 Jun 15;72(12):e1130-e1143
pubmed: 33216852
J Infect. 2020 Aug;81(2):282-288
pubmed: 32479771
Nurs Crit Care. 2021 Jul 29;:
pubmed: 34327785
Eur Rev Med Pharmacol Sci. 2021 Jun;25(11):4174-4184
pubmed: 34156699
Lancet. 2021 Oct 2;398(10307):1230-1238
pubmed: 34599878